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A B S T R A C T
Objectives: To use real-world data to develop a ﬂexible generic
decision model to predict cost, life expectancy, and quality-
adjusted life-years (QALYs) for follicular lymphoma (FL) in the
general patient population. Methods: All patients newly diagnosed
with FL in the UK’s population-based Haematological Malignancy
Research Network (www.hmrn.org) between 2004 and 2011 were
followed until 2015 (N ¼ 740). Treatment pathways, QALYs, and
costs were incorporated into a discrete event simulation to reﬂect
patient heterogeneity, including age and disease management.
Two scenario analyses, based on the latest National Institute for
Health and Clinical Excellence (NICE) guidelines (rituximab induc-
tion therapy for newly diagnosed asymptomatic patients and
rituximab maintenance therapy for patients between treatments),
were conducted and their economic impacts were compared to
current practice. Results: Incidence-based analysis revealed
expected average lifetime costs ranging from £6,165 [US$7,709] to
£63,864 [US$79,862] per patient, and average life expectancy from
75 days to 17.56 years. Prevalence-based analysis estimated aver-
age annual treatment costs of £60–65 million [US$75-80 million],
accounting for approximately 10% of the United Kingdom’s annual
National Health Service budget for hematological cancers as a
whole. Assuming that treatment effects reported in trials are
applicable to all patient groups, scenario analyses for two recent
NICE guidelines demonstrated potential annual cost savings for the
United Kingdom that ranged with uptake frequency from £0.6
million to £11 million [US$0.75-2.75 million]. Conclusions: Costs,
survival, and QALYs associated with FL vary markedly with patient
characteristics and disease management. Allowing the production of
more realistic outcomes across the patient population as a whole,
our model addresses this heterogeneity and is a useful tool with
which to evaluate new technologies/treatments to support health-
care decision makers.
Keywords: cost, cost-effectiveness analysis, discrete event simulation,
economic evaluation, follicular lymphoma, patient level simulation.
Copyright & 2018, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Introduction
Accounting for approximately 20% of all non-Hodgkin lympho-
mas (NHLs), approximately 1860 patients are newly diagnosed
with follicular lymphoma (FL) each year in the United Kingdom
[1–3]. FL, the most common of the indolent NHLs, typically
follows a remitting relapsing course; initial management ranges
from “watch-and-wait (W&W)” (active monitoring/observation) to
immediate treatment with chemotherapy/radiotherapy or pallia-
tive care. In most cases, therapy is given in response to symp-
toms, with some patients having several lines of treatment while
others remain on W&W. More recently, however, instead of
simple W&W, the use of rituximab induction therapy as a
strategy to delay the need for chemotherapy/radiotherapy has
been recommended and adopted as a treatment option in newly
diagnosed asymptomatic patients with advanced stage disease
[4]. Although FL is currently incurable, the numbers and combi-
nations of life-prolonging treatments (chemotherapies including
novel targeted agents and radiotherapy) is expanding; with
individual patients differing widely in their need for, and
response to, different treatment regimens the resulting patient
pathways are becoming increasingly complex and diverse. This
heterogeneity, coupled with the fact that FL in approximately 20%
of patients transforms to the more aggressive NHL subtype
diffuse large B-cell lymphoma (DLBCL), makes decision making
on resource allocation challenging.
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In recent years, a number of economic studies have been
carried out in FL treatment trials [5–22]. The majority of these
have focused on comparing the cost-effectiveness of administer-
ing the monoclonal antibody rituximab at particular points along
the patient pathway, either in combination with chemotherapy
(immunochemotherapy) both as ﬁrst-line therapy and subse-
quently for relapsed/refractory disease, or alone (monotherapy)
either as frontline in the W&W phase or as maintenance during
remission [7–22]. However, the ﬁndings from such studies can
provide only limited information to policymakers, not only
because they relate to selected patients at speciﬁc points in time
but also because certain groups, such as those treated palliatively
and those whose disease transforms to DLBCL, are excluded
[7–22].
The overarching aims of the present study were twofold: ﬁrst,
to provide insight into real-world FL treatment costs, survival,
and quality-adjusted life-years (QALYs), and second to develop a
generic FL model that 1) modelled the whole treatment pathway,
rather than being limited to a speciﬁc treatment line or agent, 2)
reﬂected real world practice rather than the idealized predeﬁned
setting of a randomised controlled trial, 3) predicted medical
costs, life expectancy and quality-adjusted life years (QALY)
throughout the treatment pathway, and 4) allowed different
scenarios to be run, in order to evaluate the impact of changes
in disease management on both cost and survival.
Methods
Data Sources
The individual-level data used for constructing the simulation
model are from the United Kingdom’s Haematological Malig-
nancy Research Network (https://www.HMRN.org), a specialist
population-based registry that since 2004 has tracked all patients
newly diagnosed with hematological cancers (lymphomas, leu-
kemias, and myelomas) in a catchment population of approx-
imately 3.8 million. Details of the methods underpinning HMRN
are described elsewhere [1,23,24]. Key to the present report is the
fact that HMRN has Section 251 support under the NHS Act 2006,
which allows full-treatment, response, and outcome data to be
collected to clinical trial standards regardless of patient consent,
as well as “ﬂagging” for death at the national Medical Research
Information Service (MRIS) and linkage to nationwide informa-
tion on Hospital Episode Statistics (HES).
The current study includes all 740 patients 18 years of age or
older newly diagnosed with FL (International Classiﬁcation of
Disease for Oncology, 3rd ed.: 9690/3, 9698/3) between September
1, 2004 and August 31, 2011 within HMRN’s catchment population.
For the purposes of the present analyses, all patients were followed
until August 31, 2015, death, or disease transformation to the more
aggressive DLBCL. Treatment pathways were mapped according to
the management/therapies received. A detailed summary of
patient characteristics is presented in Supplementary Table 1.
Model Structure
To reﬂect real-world treatment strategies, as well as the hetero-
geneity of patient characteristics, a discrete event simulation
(DES) model was constructed using Simul8 software (Simul8 2017
Professional version, Simul8 Corporation, Boston, MA, USA).
Figure 1 shows the model structure, which is based on real
patient pathways, clinical experience (RP, CB), and published
clinical guidelines [25]. The key input parameters used in the
model are listed in Table 1. For more details, please refer to
Supplementary Tables 2 and 3.
The model ﬁrst assigns attributes: age at diagnosis, sex, disease
stage, and prognostic index (FLIPI–FL International Prognostic Index
[26]) to a simulated patient group based on HMRN’s study popula-
tion distributions. Each patient then moves forward to the next
event, with probabilities based both on his or her own character-
istics and on his or her event history, rather than ﬁxed-time cycles.
The pathways of all simulated patients are modeled starting
from the date of diagnosis, with costs of diagnostic biopsies,
scans, electrocardiography (ECG), and echocardiography (ECHO)
included. Each patient is then assigned to one of three different
treatment options determined by his or her baseline character-
istics: W&W (with or without rituximab monotherapy), ﬁrst-line
chemotherapy or radiotherapy, or supportive end-of-life care.
Patients initially assigned to W&W can go on to receive ﬁrst-line
chemotherapy and/or radiotherapy when their cancer becomes
symptomatic, and at this point in the pathway (ﬁrst-line) radio-
therapy can be localized (stage IA disease) or palliative (symptom
control). The disease of patients on W&W may also undergo
transformation to the more aggressive, but potentially curable,
Fig. 1 – Model structure.
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Table 1 – Key parameters.
Parameters Estimates Distribution
Patient generation state
Age (years) Empirical Weibull Mean (SD): 64.0 (13.2)
Weibull (5.57, 69.33)
Age and sex
Age ≤30 Male: 0.80 Beta α ¼ 4, β ¼ 1
Age 30–40 Male: 0.60 Beta α ¼ 15, β ¼ 10
Age 40–50 Male: 0.56 Beta α ¼ 44, β ¼ 35
Age 50–60 Male: 0.45 Beta α ¼ 69, β ¼ 86
Age 60–70 Male: 0.44 Beta α ¼ 95, β ¼ 120
Age 70–80 Male: 0.47 Beta α ¼ 82, β ¼ 93
Age ≥80 Male: 0.31 Beta α ¼ 27, β ¼ 59
Initial treatment decision
Initial treatment types
Age ≤30 Chemotherapy: 0.07 Dirichlet α1 ¼ 2
Radiotherapy for stage IA: 0.00 α2 ¼ 0
Radiotherapy for IB, II, III, and IV: 0.06 α3 ¼ 1
W&W: 0.87 α4 ¼ 2
Not treated: 0.00 α5 ¼ 0
Age 30–40 Chemotherapy: 0.61 Dirichlet α1 ¼ 14
Radiotherapy for stage IA: 0.01 α2 ¼ 2
Radiotherapy for IB, II, III, and IV: 0.03 α3 ¼ 1
W&W: 0.35 α4 ¼ 8
Not treated: 0.00 α5 ¼ 0
Age 40–50 Chemotherapy: 0.40 Dirichlet α1 ¼ 36
Radiotherapy for stage IA: 0.07 α2 ¼ 4
Radiotherapy for IB, II, III, and IV: 0.08 α3 ¼ 6
W&W: 0.44 α4 ¼ 32
Not treated: 0.01 α5 ¼ 1
Age 50–60 Chemotherapy: 0.46 Dirichlet α1 ¼ 73
Radiotherapy for stage IA: 0.14 α2 ¼ 21
Radiotherapy for IB, II, III, and IV: 0.03 α3 ¼ 7
W&W: 0.37 α4 ¼ 54
Not treated: 0.00 α5 ¼ 0
Age 60–70 Chemotherapy: 0.51 Dirichlet α1 ¼ 97
Radiotherapy for stage IA: 0.11 α2 ¼ 22
Radiotherapy for IB, II, III, and IV: 0.03 α3 ¼ 11
W&W: 0.34 α4 ¼ 81
Not treated: 0.01 α5 ¼ 4
Age 70–80 Chemotherapy: 0.46 Dirichlet α1 ¼ 74
Radiotherapy for stage IA: 0.06 α2 ¼ 12
Radiotherapy for IB, II, III, and IV: 0.03 α3 ¼ 10
W&W: 0.44 α4 ¼ 77
Not treated: 0.01 α5 ¼ 2
Age ≥ 80 Chemotherapy: 0.04 Dirichlet α1 ¼ 34
Radiotherapy for stage IA: 0.06 α2 ¼ 2
Radiotherapy for IB, II, III, and IV: 0.07 α3 ¼ 5
W&W: 0.75 α4 ¼ 39
Not treated: 0.08 α5 ¼ 6
W&W decisions (induction rituximab/observation only)
Age ≤30 Induction rituximab: 0.00 Beta α ¼ 0, β ¼ 2
Age 30–40 Induction rituximab: 0.00 Beta α ¼ 0, β ¼ 8
Age 40–50 Induction rituximab: 0.00 Beta α ¼ 0, β ¼ 32
Age 50–60 Induction rituximab: 0.02 Beta α ¼ 1, β ¼ 53
Age 60–70 Induction rituximab: 0.03 Beta α ¼ 3, β ¼ 78
Age 70–80 Induction rituximab: 0.01 Beta α ¼ 1, β ¼ 76
Age ≥ 80 Induction rituximab: 0.00 Beta α ¼ 0, β ¼ 39
Utility
Pretreatment 0.83 (SE: 0.06) Beta α ¼ 31.7, β ¼ 6.49
Not treated 0.50 (SE: 0.06) Beta α ¼ 34.2, β ¼ 34.2
W&W* 0.85 (SE: 0.02) Beta α ¼ 270.1, β ¼ 47.66
First-line treatment 0.83 (SE: 0.02) Beta α ¼ 291.95, β ¼ 59.8
continued on next page
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DLBCL; and at this point patients exit the FL model and enter the
DLBCL model described in an earlier report [23].
After ﬁrst-line treatment, one of three events can occur: entry
to a period of observation (FL responded to treatment) or, for
those who are refractory to treatment, further treatment or
death, with the probabilities of these outcomes varying with
the type of ﬁrst-line therapy received, cancer stage, and age at
diagnosis. Subsequently, patients on observation can receive
second-line treatment because of relapse or exit because of death
or transformation to DLBCL. Second-line chemotherapy regimens
may differ from ﬁrst line, and stem cell transplants (SCTs,
autologous or allogeneic) may also be given at this point. After
second-line treatment, patients may enter a further period of
observation and some will go on to receive third-line treatments.
In our data, relatively few patients received treatment post third
line and, for modeling purposes, it was assumed that the treat-
ment patterns and response rates were similar to those observed
at third line.
Model Inputs
Medical costs
The model was built from a NHS perspective; the FL-related
medical costs considered those associated with diagnosis, mon-
itoring, treatment, as well as those for supportive and end-of-life
care. All treatment details were derived from HMRN’s population-
based cohort, and all resource usage, including outpatient visits,
day case, inpatient stays, intensive care, and managing treat-
ment side effects/complications (when the episode was related to
FL; International Classiﬁcation of Diseases 10th Revision [ICD 10]
code C82) were derived from HES data. Details of the cost items
and different chemotherapy regimens included in each costing
phase are in Supplementary Table 4.
The cost information (unit costs) used in the model are
summarized in Table 2 and are expressed in 2016 UK sterling
and 2016 US dollar (£1 = US$1.2505). Parameters were obtained
from three sources: the National Tariff 2016/17 for
Table 1 – continued
Parameters Estimates Distribution
First remission 0.88 (SE: 0.01) Beta α ¼ 928.4, β ¼ 126.6
Subsequent treatment* 0.62 (SE: 0.06) Beta α ¼ 161.68, β ¼ 99.1
Subsequent remission* 0.79 (SE: 0.03) Beta α ¼ 144.83, β ¼ 38.5
W&W, watch and wait.
* The utilities were derived from Wilder 2006 [39].
Table 2 – Summary of key unit costs.
Unit cost Source
Inpatient stay
Spell cost £759 National Tariff
Cost per excess bed day £232 National Tariff
Outpatient visit
First attendance (single professional) £288 National Tariff
First attendance (multiple professional) £463 National Tariff
Follow–up visit (single professional) £120 National Tariff
Follow–up visit (multiple professional) £216 National Tariff
Radiotherapy
Planning £769 National Tariff
Per fraction £120 National Tariff
Chemotherapy (per cycle)
CVP £300 Leeds Teaching Hospital Trust
R-CVP £1,560 Leeds Teaching Hospital Trust
CHOP £303 Leeds Teaching Hospital Trust
R-CHOP £1,817 Leeds Teaching Hospital Trust
Chlorambucil £102 Leeds Teaching Hospital Trust
R-Chlorambucil £1,867 Leeds Teaching Hospital Trust
Bendamustine £5,089 Leeds Teaching Hospital Trust
R-Bendamustine £6,855 Leeds Teaching Hospital Trust
DHAP £609 Leeds Teaching Hospital Trust
R-DHAP £2,050 Leeds Teaching Hospital Trust
R-ESHAP £3,511 Leeds Teaching Hospital Trust
Transplant
Autograft bone marrow transplant £5,786 Reference cost
Allogeneic bone marrow transplant £46,608 Reference cost
R-Bendamustine, bendamustine, and rituximab; R-Chlorambucil, chlorambucil, and rituximab; CHOP, cyclophosphamide, doxorubicin,
vincristine, and prednisone; R-CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab; CVP, cyclophosphamide,
vincristine, and prednisone; R–CVP, cyclophosphamide, vincristine, prednisone, and rituximab; DHAP, dexamethasone, cytarabine, and
cisplatin; R–DHAP, dexamethasone, cytarabine, cisplatin, and rituximab; R–ESHAP, etoposide, methylprednisolone, cytarabine, cisplatin, and
rituximab.
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reimbursement/expenditure of NHS treatments [27], Leeds
Teaching Hospital NHS Trust for chemotherapy costs that are
locally negotiated, and the inﬂated NHS reference cost 2015/16
when other sources were not available [28].
Time-to-event
To construct the discrete event simulation model, several time-
to-event (TTE) analyses were performed using empirical data to
estimate the distributions associated with time between two
events. This included the time from diagnosis to treatment,
duration of treatment, time from response to next treatment,
time from response to death, time from response to disease
transformation, and time in end-of-life care. To extrapolate
beyond the end of follow-up (August 2015), parametric survival
analyses were performed based on best-ﬁt distributions as a
function of the patient’s age, treatment details, and response. Six
parametric distributions (normal, exponential, Weibull, gamma,
log-normal, and log-logistic distributions) were tested, and the
best ﬁt model was determined using Akaike Information Criteria
(AIC) score and Bayesian information criteria (BIC) [29]. The
observed and best ﬁt Kaplan–Meier time to event curves used in
the model are shown in Figure 2. More details are provided in
Supplementary Table 5. To allow study subjects to proceed from
one event to the next, the times to the next possible event are
sampled and compared, and the event that occurs ﬁrst is taken as
the next event. With this mechanism, we were able to model all
the patients in the study through their treatment pathways from
diagnosis to death.
Utility
The utility values incorporated into the model were derived
directly from a subgroup study of 181 patients with FL diagnosed
between 2012 and 2016, all of whom completed EQ-5D-5L ques-
tionnaires around the time of diagnosis, and then at 6 to 12
months thereafter until the end of follow-up (January 1, 2017).
Information from the published literature was used when the
number of patients in a health phase was too small for analysis
(fewer than ﬁve). A summary of the utilities in each health phase
is provided in Table 1.
Model Outputs
Health outcome was measured by life-years (LYs) and QALYs,
while economic outcome was captured by treatment costs. Both
economic and health outcomes were discounted using a 3.5%
annual discount rate, based on UK guidance recommended by the
National Institute for Health and Clinical Excellence (NICE) [30].
Assessing Uncertainty
Probabilistic sensitivity analysis was performed on all parameters
to explore the cumulative uncertainty of the model and possible/
likely outcomes. Each parameter was assigned a distribution to
reﬂect sample variability (e.g., beta distributions were used for
binominal events), while coefﬁcients of survival models were
assigned multivariate normal distributions using the variance
and covariance matrix of the coefﬁcients. Then, Monte Carlo
simulations were performed by sampling parameters from the
corresponding distributions simultaneously 1000 times; stable
results occurred in this study before 1000 was reached. All
outputs from the iterations were summarized with 95% conﬁ-
dence intervals [31].
Analysis
Base case
To investigate the economic impact of FL across the United
Kingdom as a whole, the annual number of expected cases
(N ¼ 1860) estimated by HMRN (https://www.hmrn.org/statis
tics/incidence) was used in the model. To explore the effects of
the time horizon on cost, QALYs, and survival, results are
presented in aggregate and for the time horizons of 5 years, 10
years, 15 years, 20 years, 25 years, 30 years, and lifetime
(simulated until 100 years of age or death). The model further
generated prevalence-based estimates, calculating the annual
impacts on cost, Lys, and QALYs for treating new and existing
FL patients in the United Kingdom. The rate of entry into the
model was determined by the incidence rate, and results were
collected after a burn-in period of 30 years.
Scenarios
To explore the impact of current and future policy changes, the
model was used in two scenarios. Scenario 1 was based on recent
UK NICE guidelines [32]: Patients with FL who are not sympto-
matic at diagnosis can be given rituximab once a week for 4
weeks as part of the W&Wmanagement strategy. To evaluate the
economic impact of this change, we modeled uptake frequencies
of 25%, 50%, 75%, and 100% and combined the costs from our
observational data with the efﬁcacy ﬁndings from the trial [4],
which reported that monotherapy rituximab signiﬁcantly delayed
the need for subsequent chemotherapy/radiotherapy treatment
(hazard ratio [HR]: 0.35, 95% CI: 0.22–0.56). Scenario 2 was based
on another NICE appraisal [33]: FL patients who respond to
treatment may also be given rituximab once every 2 months for
a maximum of 2 years. To estimate the economic impact of this
change, we again modeled uptake frequencies of 25%, 50%, 75%,
and 100% and used the costs from our observational data and the
ﬁndings from the trial, in which rituximab was reported to have
Fig. 2 – Time-to-event analyses. (A) Time in W&W and in end-of-life care. (B) Time from treatment to death, transformation, or
response. (C) Time from response to death or next treatment.
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Table 3 – Simulated medical costs, LYs, and QALYs across treatment pathway over a life–time horizon for FL (N ¼ 1860).
Incidence–based results
Total (FL costs alone) Total FL þ DLBCL Prevalence–based
results
Cost (£) LYs QALYs Cost (£) LYs Annual cost
N mean (95% CI) mean (95% CI) mean (95%CI) mean (95% CI) mean (95% CI) Million (£)
Total 1860 18,705 (18,631–18,781) 9.08 (9.06–9.11) 7.35 (7.34–7.37) 23,122 (23,042–23,201) 11.41 (11.38–11.43) 61.6 (59.2–64.0)
W&W only 550 (548–551) 5,296 (5,290–5,301) 8.22 (8.20–8.24) 7.40 (7.38–7.41) 11,818 (11,794–11,842) 11.61 (11.58–11.63) 18.2 (17.4–18.9)
Treated 1,273 (1,271–1,274) 24,872 (24,765–24,979) 9.72 (9.69–9.75) 8.46 (8.43–8.48) 28,509 (28,394–28,624) 11.65 (11.62–11.68) 42.1 (40.4–43.8)
First line only 720 (717–722) 13,456 (13,388–13,525) 8.27 (8.24–8.31) 8.07 (8.06–8.14) 16,658 (16,581–16,735) 10.01 (9.98–10.05) 23.8 (22.8–24.8)
Second line plus
With SCT 77 (76–78) 60,261 (59,791–60,730) 15.79 (15.70–15.87) 12.15 (12.09–12.21) 63,864 (63,376–64,351) 17.56 (17.47–17.64) 2.5 (2.4–2.7)
Without SCT 499 (497–502) 36,000 (35,828–36,171) 10.85 (10.81–10.90) 8.34 (8.30–8.38) 40,123 (39,936–40,309) 12.99 (12.94–13.05) 16.5 (15.8–17.2)
Not treated 37 (36–38) 6,165 (6,093–6,237) 0.21 (0.20–0.21) 0.12 (0.12–0.12) 6,165 (6,093–6,237) 0.21 (0.20–0.21) 1.2 (1.1–1.3)
95% CI, 95% conﬁdence interval; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; LY, life-year; QALY, quality-adjusted life-year; SCT, stem cell transplant (including allograft/
autologous SCT); W&W, watch and wait.
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delayed the need for second-line treatment (HR: 0.55, 95% CI:
0.44–0.68) [34], to model efﬁcacy.
Validation
The model was validated using standard methods, including face,
as well as internal and external validations [35]. Face validation
on model structure and data sources was conducted while the
model was under construction by consulting clinical experts.
Internal validation was assessed by comparing predicted costs
and LYs with empirical estimates, and external validation was
performed by comparing simulated results with the ﬁndings from
the relevant literature.
Results
Incidence-Based Results
Predicted lifetime costs, LYs, and QALYs are presented in Table 3;
the detailed predicted resource use (quantity) can be found in
Supplementary Table 6. Overall, the average cost per patient was
around £18,705 [US$23,390], excluding the impact of
transformation to DLBCL. As expected, costs for patients who
received treatment with curative intent were higher (£24,872
[US$31,102]) than for those who did not. The highest lifetime
costs occurred among patients who received second-line treat-
ment that included an SCT (£60,261 [US$75,356]), but this was
accompanied by the longest survival (15.79 LYs). Those who were
asymptomatic and remained on W&W throughout incurred the
lowest costs (£5,296 [US$6,622]), but had LYs (8.22 LYs) similar to
those who were treated (9.72 LYs).
To include the impact of transformation to DLBCL on costs
and LYs, the model further simulated patients beyond trans-
formation to DLBCL, using previous results [25]. As shown in
Table 3, the average cost and LY per patient were £23,122
[US$28,914] and 11.41 years, respectively. Compared to the results
that included FL-related elements alone, the differences were
considerable (around £4,400 [US$5,502] and 2.33 LYs).
Predicted average costs and LYs for 1000 iterations over
different time horizons are presented in Figure 3. Results for
different time horizons provide insight into the overall economic
and health impact across the treatment pathway; results for
shorter periods (5-year, 10-year, 15-year, 20-year, 25-year, and 30-
year) allowed external validation and exploration of time horizon
impact. As shown, the average costs (including treatment
Fig. 3 – Estimated average costs and LYs per patient over different time horizons (1000 iterations).
Table 4 – Scenario analysis results based on uptake frequencies and treatment effects.
Uptake frequency Scenario 1: Rituximab during W&W* Scenario 2: Rituximab during observation†
Mean cost (min–max) £ Mean cost (min–max) £
Base case‡ 61.6 Million (59.2–64.0 million) 61.6 Million (59.2–64.0 million)
25% 60.5 Million (57.1–63.9 million) 58.6 Million (57.1–60.4 million)
50% 60.3 Million (57.8–62.1 million) 55.9 Million (53.0–57.9 million)
75% 59.5 Million (57.7–61.6 million) 54.2 Million (52.6–55.7 million)
100% 58.7 Million (56.8–60.4 million) 52.3 Million (50.3–53.6 million)
W&W, watch and wait.
* Based on the trial effect size of hazard ratio 0.35; 95% conﬁdence intervals 0.22–0.56 [4].
† Based on the trial effect size of hazard ratio 0.55; 95% conﬁdence intervals (0.44–0.68) [33].
‡ Current study; 2% of patients received rituximab during W&W, and 15% during subsequent periods of observation/maintenance.
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following transformation) per patient were £21,761 [US$27,212],
£22,399 [US$28,010], £22,718 [US$28,409], and £23,121 [US$28,913]
for the 20-year, 25-year, 30-year, and lifetime horizons respec-
tively. The cost continued to increase throughout the time
horizons, as did the predicted LYs (10.1, 10.8, 11.0, and 11.4 for
20-year, 25-year, 30-year, and lifetime horizons, respectively).
Prevalence-Based Results
Prevalence-based costs provide estimates of the total cost asso-
ciated with treating existing and new FL patients in a 1-year
period. The simulation results demonstrate that the annual cost
for treating FL across the United Kingdom as a whole was in the
region of £50 million [US$62.5 million] for the lower bound and
£60 million [US$75 million] for the upper bound (data not shown);
the annual cost including treatment following transformation to
DLBCL was in the region of £60 million to £65 million [US$75-80
million] (Table 3).
Scenario Analyses
Extrapolating the effect size shown in the trial (HR point estimate
0.35) to the general patient population, Table 4 demonstrates the
economic impact of introducing ﬁrst-line rituximab to patients
who are currently managed on W&W without rituximab mono-
therapy. As shown, the estimated annual cost of treating new
and existing FL patients would decrease by approximately £2.4
million to £3.6 million [US$3.0-4.5 million] if uptake was 100%,
£1.5 million to £2.4 million [US$1.9-3.0 million] for 75%, £1.4
million to £1.9 million [US$1.8-2.4 million] for 50%, and £0.1
million to £2.1 million [US$0.1-2.6 million] for 25% (including
costs associated with transformation to DLBCL).
Likewise, Table 4 shows the economic impact of introducing
rituximab to patients in remission, assuming the trial effect size
can be extrapolated to the patient population as a whole (HR
point estimate 0.55). Despite extra spending on the cost of
maintenance rituximab, the estimated annual costs would
decrease by around £8.9 million to £10.4 million [US$75-80
million] when uptake rate is 100%, £6.6 million to £8.3 million
[US$8.3-10.4 million] for 75%, £5.7 million to £6.1 million [US$7.1-
7.6 million] for 50%, and £3.0 million to £3.6 million [US$3.7-4.5
million] for 25% when transformation to DLBCL is taken into
consideration.
Model Validation
Regarding face validity, the model structure, parameters, and
results were checked and approved by the clinical authors (RP,
CB). For internal validity, both simulated cost and survival out-
comes were compared to empirical estimates derived from the
study population (HMRN). The model was simulated to mirror
that of the study population, allowing patients to enter the model
for 7 years (2004–11) at a constant rate until 740 was reached, and
then further modeling for another 4 years. The simulated time to
event data closely matched the observed data (the Kaplan–Meier
curves are compared in Supplementary Fig. 1). The results from
1000 iterations produced average treatment costs and survival
days for all patients (Fig. 4) that were similar to the empirical
data. The average duration of disease (from date of diagnosis to
either death or modelling end date) was 2378 days per patient
(ranging from 2142 to 2608 days across 1000 iterations) and
captured 99% of the actual observed time (2395 days). The
average simulated cost was £17,331 [US$21,672] per patient
(ranging from £14,746 [US$18,440] to £20,556 [US$25,705] across
1000 iterations), which slightly overestimated the empirical
results derived from the study population (£17,052 [US$21,324]).
The same pattern was observed in the simulation results for each
line of treatment (Fig. 4).
With regard to external validity, the simulated cost and
survival results were broadly similar to ﬁndings reported in the
relevant literature (see Supplementary Table 7).
Discussion
This is the ﬁrst FL model to simulate individual patients’ medical
costs, LYs, and QALYs along the full patient pathway. The
analysis revealed that although FL is a comparatively rare cancer
(annual incidence rate is 3.3 per 100,000) and the average treat-
ment cost per patient is relatively modest (£23,122 [US$28,914]),
the economic impact of treating new and existing FL patients is
signiﬁcant; the annual cost in the United Kingdom lies in the
region of £60 million to £65 million [US$75-80 million], accounting
for approximately 10% of the annual NHS budget for hematolog-
ical cancers as a whole [36]. Our analysis also conﬁrmed the
underlying heterogeneity of the FL patient population; the
expected lifetime medical cost ranged from £6,165 [US$7,709] to
Fig. 4 – Model validation.
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£63,864 [US$79,862] per patient and life expectancy from 75 days
to 17.56 years (see Table 3 and Supplementary Table 8 for more
details). In this context, the application of “averages” may not be
appropriate in all situations.
The importance of adopting a lifetime horizon approach was
also demonstrated in the current study. The differences in
estimated costs derived from 20-year, 25-year, and 30-year
horizons were relatively minor, reﬂecting the fact that the
majority of the treatment occurred in the ﬁrst 20 years. However,
the differences in estimated LYs were considerable, conﬁrming,
as has been suggested by others, that the lifetime horizon is the
optimal approach as it allows the overall effect of treatment to be
fully captured. As such, results from studies using time horizons
of less than 20 years need to be interpreted cautiously, as the
results are unlikely to reﬂect true differences in LYs.
To demonstrate the ﬂexibility/adaptability of the generic
model developed in the current study, we tested two scenarios
based on NICE guidelines and explored their annual economic
impacts on the health care system using effect sizes reported in
clinical trials [4,34], which may or may not be generalizable to the
patient population as a whole. In this context, the model
performed well, producing results that are broadly consistent
with the ﬁndings from relevant trial-based literature, although
the costs for both scenarios were on the lower side
[10,11,14,16,18,20–22]. In addition, although both scenarios dem-
onstrated expected savings, wider dispersion of annual economic
impact was observed in Scenario 2. This could possibly be
because cost savings are driven not only by the reported treat-
ment effects and uptake frequencies, but also by the number of
patients who will beneﬁt and whether the need for subsequent
treatment can be prevented. Furthermore, although potential
cost savings are conﬁrmed, such estimates need to be interpreted
cautiously, as they are applicable only in situations in which
treatment effects derived from trial populations extrapolate to
the general patient population. Importantly, however, the model
has the ability to accommodate heterogeneity and, as new data
emerge, the estimates can be reﬁned to more accurately reﬂect
the real-world impact. In addition, the generic approach could aid
future cost-effectiveness studies examining new interventions,
including, for example, the introduction of biosimilars for ritux-
imab, the usage of which is increasing now that the original
patent has expired [37,38].
The ability to model patient pathways in a more granular
fashion than is usually the case is a major strength of our
approach. This more realistic structure allows the model to more
closely mirror clinical practice, enabling differences in cost and
health outcomes to be characterized more effectively. The incor-
poration of real-world QALY information, rather than hypothet-
ical ﬁgures, also means that more reliable QALY results relating
to FL treatment can be predicted. Another strength of this study
is the ﬂexibility/adaptability of the model, which allows param-
eters to be varied and different time horizons to be adopted,
permitting the model to evaluate different types of intervention,
health care settings, and diseases. A tutorial video demonstrating
the ﬂexibility of the interactive model can be found at https://
www.hmrn.org/economics/models. In addition, the model can
simulate both open and closed cohorts to answer prevalence-
and incidence-based questions. Furthermore, the model has the
potential and ﬂexibility to evaluate treatment sequences,
although such analysis is currently outside the scope of the
present study. It is important to note, however, that others have
used similar modeling techniques to explore the optimal treat-
ment sequence for the management of conditions where options
change as the disease progresses [15,39–42]. Like our approach,
these studies modeled patients through their pathways; the main
difference was that they simulated a set of key treatment
sequences one at a time, rather than all treatment pathways/
sequences at the same time [15,39–42]. The main beneﬁt of
modeling all treatment pathways at the same time is the ability
to demonstrate impacts in the real-world setting, hence allowing
policymakers to make more informed decisions.
Our study is subject to some limitations, primarily those
relating to the extrapolation of data. For example, we used
parametric disease-free techniques to extrapolate survival
beyond the 10-year follow-up period, having conﬁrmed that the
observed survival differed from that reported in UK life tables.
Likewise, data relating to QALYs were derived from a subgroup of
patients who could potentially differ in important characteristics
from the patient population as a whole (the impact of utilities on
QALY estimates is presented in Supplementary Fig. 2). Further-
more, because this is an observational study, it is difﬁcult to
compare the efﬁcacy of different regimens, as treatment is not
randomly assigned. Finally, as HMRN is an ongoing cohort with
continued ascertainment and follow-up, although it was not
possible in the present report to estimate utilities by chemo-
therapy regimen owing to small numbers, more empirical data
will be available in time, allowing further reﬁnement of the
results.
Conclusion
The analyses presented here conﬁrm that costs, survival, and
QALYs associated with FL vary markedly with patient character-
istics and disease management. Based on real-world patient level
data, our model addresses this heterogeneity, allowing the
production of more realistic outcomes across the patient pop-
ulation as a whole. Future application of the model will include
evaluation of new technologies/treatments to support health care
decision makers, especially in the era of personalized medicine.
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